Ophthalmology. RetinaPub Date : 2026-10-01Epub Date: 2026-06-03DOI: 10.1016/j.oret.2026.05.018
David S. Boyer MD, Leonide Saad PhD, Ilyas Washington PhD, Alexander Melamud MD, Kenneth B. Graham MD, Adrian E. O’Malley MD, Gabrielle M. DeBartolomeo ACRP-CP, Honghua Jiang PhD, Lindsey D. Harris MD, Christine N. Kay MD, Philip J. Ferrone MD, Seemi Khan MD, SAGA Study Team
{"title":"Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration","authors":"David S. Boyer MD, Leonide Saad PhD, Ilyas Washington PhD, Alexander Melamud MD, Kenneth B. Graham MD, Adrian E. O’Malley MD, Gabrielle M. DeBartolomeo ACRP-CP, Honghua Jiang PhD, Lindsey D. Harris MD, Christine N. Kay MD, Philip J. Ferrone MD, Seemi Khan MD, SAGA Study Team","doi":"10.1016/j.oret.2026.05.018","DOIUrl":"10.1016/j.oret.2026.05.018","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the effects of gildeuretinol acetate (C20D3-vitamin A) in geographic atrophy (GA).</div></div><div>To assess the effects of gildeuretinol acetate (C20D3-vitamin A) in geographic atrophy (GA).</div><div><h3>Design</h3><div>A 24-month, double-masked, multicenter, randomized, placebo-controlled trial.</div></div><div>A 24-month, double-masked, multicenter, randomized, placebo-controlled trial.</div><div><h3>Participants</h3><div>Participants aged ≥60 years with GA.</div></div><div>Participants aged ≥60 years with GA.</div><div><h3>Interventions</h3><div>Randomized 2:1 to oral gildeuretinol acetate 14 mg daily or placebo.</div></div><div>Randomized 2:1 to oral gildeuretinol acetate 14 mg daily or placebo.</div><div><h3>Main Outcome Measures</h3><div>The primary endpoint was GA growth rate from baseline to 24 months. A prespecified sensitivity analysis accounted for a 6-month delay in onset of therapeutic effect. Secondary endpoints included change from baseline in low-luminance visual acuity (LLVA), best-corrected visual acuity (BCVA), Visual Function Questionnaire-25, and Functional Reading Independence (FRI) Index.</div></div><div>The primary endpoint was GA growth rate from baseline to 24 months. A prespecified sensitivity analysis accounted for a 6-month delay in onset of therapeutic effect. Secondary endpoints included change from baseline in low-luminance visual acuity (LLVA), best-corrected visual acuity (BCVA), Visual Function Questionnaire-25, and Functional Reading Independence (FRI) Index.</div><div><h3>Results</h3><div>Among 198 randomized participants (mean [standard deviation {SD}] age, 78.4 [7.0] years; 68.7% women), 69.2% completed the 24-month study. In the gildeuretinol and placebo groups, baseline mean (SD) total GA lesion area in mm<sup>2</sup> was 7.72 (6.10) and 7.09 (4.16); BCVA letter scores were 56.2 (21.3) (Snellen equivalent: ∼20/80) and 58.8 (18.0) (∼20/70); and LLVA letter scores were 31.1 (19.0) (∼20/200) and 31.6 (17.8) (∼20/250), respectively. Mean GA growth rates were 1.62 mm<sup>2</sup>/yr with gildeuretinol and 1.87 mm<sup>2</sup>/yr with placebo (least squares [LSs] mean difference: –0.25 mm<sup>2</sup>/yr; 95% confidence interval [CI]: –0.53 to 0.03; <em>P</em> = 0.075), a 13.4% relative reduction for gildeuretinol versus placebo. The LS mean (standard error) GA growth rates from 6 to 24 months were 1.90 (0.12) mm<sup>2</sup>/yr (placebo) and 1.61 (0.08) mm<sup>2</sup>/yr (gildeuretinol), a 15.3% relative reduction (–0.29 mm<sup>2</sup>/yr; 95% CI: –0.576 to –0.004; nominal <em>P</em> = 0.047). At 24 months, LLVA declined 3.9 and 8.3 ETDRS letters in the gildeuretinol and placebo groups, respectively (difference: 4.4 letters; 95% CI: 0.40–8.41; nominal <em>P</em> = 0.031). Best-corrected visual acuity declined 6.9 letters with gildeuretinol and 10.2 letters with placebo (difference: 3.3 letters; 95% CI: –0.63 to 7.23; <em>P =</em> 0.099). Visual Function Questionnaire-25 score","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages 1027-1035"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ophthalmology. RetinaPub Date : 2026-10-01Epub Date: 2026-05-23DOI: 10.1016/j.oret.2026.05.011
Peizeng Yang MD, PhD, Lan Xia MD, PhD, Aniruddha Agarwal MD, PhD, Rupesh Agrawal FRCS, Annabelle A. Okada MD, MPH, Debra A. Goldstein MD, Timothy M. Janetos MD, Pınar Çakar Özdal MD, Padmamalini Mahendradas MD, Ester Carreño MD, PhD, Heloisa Nascimento MD, PhD, Massimo Accorinti MD, PhD, Sapna Gangaputra MD, MPH, Alessandro Invernizzi MD, PhD, Douglas A. Jabs MD, MBA, Janet L. Davis MD, Marc D. de Smet MD, PhD, SriniVas R. Sadda MD, David Sarraf MD, Vishali Gupta MD, Vishali Gupta
{"title":"Evidence and Consensus-Based Guidelines in Vogt-Koyanagi-Harada Disease","authors":"Peizeng Yang MD, PhD, Lan Xia MD, PhD, Aniruddha Agarwal MD, PhD, Rupesh Agrawal FRCS, Annabelle A. Okada MD, MPH, Debra A. Goldstein MD, Timothy M. Janetos MD, Pınar Çakar Özdal MD, Padmamalini Mahendradas MD, Ester Carreño MD, PhD, Heloisa Nascimento MD, PhD, Massimo Accorinti MD, PhD, Sapna Gangaputra MD, MPH, Alessandro Invernizzi MD, PhD, Douglas A. Jabs MD, MBA, Janet L. Davis MD, Marc D. de Smet MD, PhD, SriniVas R. Sadda MD, David Sarraf MD, Vishali Gupta MD, Vishali Gupta","doi":"10.1016/j.oret.2026.05.011","DOIUrl":"10.1016/j.oret.2026.05.011","url":null,"abstract":"<div><h3>Purpose</h3><div>To develop imaging and consensus-based guidelines for the application of multimodal imaging in the diagnosis, assessment of disease activity, and detection of complications in Vogt-Koyanagi-Harada (VKH) disease.</div></div><div>To develop imaging and consensus-based guidelines for the application of multimodal imaging in the diagnosis, assessment of disease activity, and detection of complications in Vogt-Koyanagi-Harada (VKH) disease.</div><div><h3>Design</h3><div>Consensus agreement guided by systematic literature review and expert committee deliberation using a nominal group technique (NGT).</div></div><div>Consensus agreement guided by systematic literature review and expert committee deliberation using a nominal group technique (NGT).</div><div><h3>Participants</h3><div>International uveitis and retina specialists participating in the Multimodal Imaging in Uveitis (MUV) taskforce.</div></div><div>International uveitis and retina specialists participating in the Multimodal Imaging in Uveitis (MUV) taskforce.</div><div><h3>Methods</h3><div>A panel of experts independently reviewed published literature and representative cases of active, resolved, and late-stage VKH disease, using multimodal imaging modalities: color fundus photography (CFP), OCT, fundus autofluorescence (FAF), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), and OCT angiography (OCTA). Structured NGT sessions were conducted to define consensus-based imaging descriptors of active and resolved VKH disease, plus VKH complications including retinal pigment epithelium disruption, choroidal neovascularization (CNV), subretinal fibrosis, and other sequelae.</div></div><div>A panel of experts independently reviewed published literature and representative cases of active, resolved, and late-stage VKH disease, using multimodal imaging modalities: color fundus photography (CFP), OCT, fundus autofluorescence (FAF), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), and OCT angiography (OCTA). Structured NGT sessions were conducted to define consensus-based imaging descriptors of active and resolved VKH disease, plus VKH complications including retinal pigment epithelium disruption, choroidal neovascularization (CNV), subretinal fibrosis, and other sequelae.</div><div><h3>Main Outcome Measures</h3><div>Identification of reproducible multimodal imaging features of VKH and imaging criteria for determining disease activity and complications.</div></div><div>Identification of reproducible multimodal imaging features of VKH and imaging criteria for determining disease activity and complications.</div><div><h3>Results</h3><div>The experts agreed that active VKH diagnosis is supported by characteristic imaging findings in the early stages, including bilateral multifocal serous retinal detachments and optic disc hyperemia on CFP, multiloculated subretinal fluid and choroidal thickening on OCT, and round-to-oval hypofluor","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages e109-e125"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148006091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ophthalmology. RetinaPub Date : 2026-10-01Epub Date: 2026-06-05DOI: 10.1016/j.oret.2026.05.019
Martina C. Herwig-Carl MD, Karin U. Loeffler MD, Yannick N. Liermann MD, Louisa M. Bulirsch MD, Raffael Liegl MD, Ralf Hornig PhD, Daniel Palanker PhD, Adnan Kilani MD, Thomas Ach MD, José-Alain Sahel MD, Armin Wolf MD, Frank G. Holz MD
{"title":"Histologic Findings after Subretinal Implantation of the PRIMA Photovoltaic Array in Patients with Geographic Atrophy due to Age-Related Macular Degeneration","authors":"Martina C. Herwig-Carl MD, Karin U. Loeffler MD, Yannick N. Liermann MD, Louisa M. Bulirsch MD, Raffael Liegl MD, Ralf Hornig PhD, Daniel Palanker PhD, Adnan Kilani MD, Thomas Ach MD, José-Alain Sahel MD, Armin Wolf MD, Frank G. Holz MD","doi":"10.1016/j.oret.2026.05.019","DOIUrl":"10.1016/j.oret.2026.05.019","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the histologic findings 7 weeks and 18 months after subretinal implantation of the PRIMA photovoltaic array in eyes with geographic atrophy.</div></div><div>To describe the histologic findings 7 weeks and 18 months after subretinal implantation of the PRIMA photovoltaic array in eyes with geographic atrophy.</div><div><h3>Design</h3><div>Comparative case series.</div></div><div>Comparative case series.</div><div><h3>Subjects and Controls</h3><div>Four globes of 2 deceased study participants from the prospective PRIMAvera study were analyzed.</div></div><div>Four globes of 2 deceased study participants from the prospective PRIMAvera study were analyzed.</div><div><h3>Methods</h3><div>The subretinal implant was removed after horizontal sectioning of the globe. Serial sections were performed and stained with hematoxylin-eosin, Masson trichrome, as well as periodic acid–Schiff for histopathologic analysis. Selected sections were immunohistochemically stained for CD68, CD163, GFAP, CD31, CK18, ARR3, RBPMS, and TRPM1. Both study and fellow eyes were analyzed.</div></div><div>The subretinal implant was removed after horizontal sectioning of the globe. Serial sections were performed and stained with hematoxylin-eosin, Masson trichrome, as well as periodic acid–Schiff for histopathologic analysis. Selected sections were immunohistochemically stained for CD68, CD163, GFAP, CD31, CK18, ARR3, RBPMS, and TRPM1. Both study and fellow eyes were analyzed.</div><div><h3>Main Outcome Measures</h3><div>The histopathologic analysis focused on the anatomical implant localization, wound healing processes, potential inflammatory reactions adjacent to the implant and at the retinotomy site, the development of retinal gliosis and retinal atrophy. as well as a potential encapsulation.</div></div><div>The histopathologic analysis focused on the anatomical implant localization, wound healing processes, potential inflammatory reactions adjacent to the implant and at the retinotomy site, the development of retinal gliosis and retinal atrophy. as well as a potential encapsulation.</div><div><h3>Results</h3><div>Both implants could be removed in toto without obvious retinal trauma. Histologically, the implants were located at the level of the outer plexiform layer, as intended, close to the inner nuclear layer. A tissue layer was identified beneath the implant, consisting of a basement membrane deposit and cellular components. A small rupture of Bruch’s membrane was detected (in the globe with an 18-months follow-up) associated with localized subretinal fibrosis. At the implant-retina interface, there was only a minimal tissue response without pseudocapsule formation. Furthermore, no significant inflammatory response was detected. The retina overlying the implant was comparable with the fellow eyes in most areas, with limited focal atrophy of the inner retina 18 months after PRIMA implantation. At the retinotomy site, a full-thickness sca","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages 1036-1046"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148194768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ophthalmology. RetinaPub Date : 2026-10-01Epub Date: 2026-06-22DOI: 10.1016/j.oret.2026.06.007
Charles Zhang MD, Katherine E. Bowers BS, Victor Sanchez MD, Sinan Ersan BS, Basil K. Williams Jr. MD, Harry W. Flynn Jr. MD, Nicolas A. Yannuzzi MD
{"title":"Outcomes of Laser Retinopexy for Retinal Tears by Fellow-Eye Detachment History","authors":"Charles Zhang MD, Katherine E. Bowers BS, Victor Sanchez MD, Sinan Ersan BS, Basil K. Williams Jr. MD, Harry W. Flynn Jr. MD, Nicolas A. Yannuzzi MD","doi":"10.1016/j.oret.2026.06.007","DOIUrl":"10.1016/j.oret.2026.06.007","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages 1056-1058"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ophthalmology. RetinaPub Date : 2026-10-01Epub Date: 2026-08-16DOI: 10.1016/j.oret.2026.06.005
Mathew W. MacCumber MD, PhD, Nathan G. Vance BSPH, Nitika Aggarwal BTech
{"title":"Tetracycline-class Antibiotics for Proliferative Retinopathy Prevention: Still Too Many Unanswered Questions","authors":"Mathew W. MacCumber MD, PhD, Nathan G. Vance BSPH, Nitika Aggarwal BTech","doi":"10.1016/j.oret.2026.06.005","DOIUrl":"10.1016/j.oret.2026.06.005","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages 981-983"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}